News

Follow our progress

Keep on top of updates through our press releases.

Filter by

News

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that…

Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE)…

LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to…

LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at…

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet…

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m….

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that…

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its…

Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST…

Developing novel therapeutics for respiratory diseases

Inquires from press and journalists are welcome.